Adv Ther (2018) 35:768–778 https://doi.org/10.1007/s12325-018-0701-5 ORIGINAL RESEARCH Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER22 Metastatic Breast Cancer . . . Anand A. Dalal Patrick Gagnon-Sanschagrin Rebecca Burne . . . Annie Gue ´ rin Genevie `ve Gauthier Tania Small Polly Niravath Received: February 15, 2018 / Published online: June 4, 2018 Springer Healthcare Ltd., part of Springer Nature 2018 Methods: A large US claims database was used ABSTRACT to identify postmenopausal women with HR?/ HER2- mBC who received a palbociclib-based Introduction: Targeted therapies have revolu- therapy during one of their ﬁrst three lines of tionized the treatment of hormone receptor therapy for mBC between February 2015 (pal- positive/human epidermal growth factor recep- bociclib approval) and December 2015. Dosing tor 2 negative (HR?/HER2-) metastatic breast patterns (dosing modiﬁcations and sequences) cancer (mBC). However, as for many oncology were reported; a dose modiﬁcation was deﬁned drugs, the dose of targeted therapies may need as an increase/decrease of at least 25 mg daily to be adjusted over time, leading to drug compared to the preceding dose. Estimates of wastage when a dose modiﬁcation is needed but drug wastage costs were based on days with the dose cannot be
Advances in Therapy – Springer Journals
Published: Jun 4, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud